| Pharmaceutical Information |
| Drug Name |
Glatiramer |
| Drug ID |
BADD_D01020 |
| Description |
Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis. |
| Indications and Usage |
For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AX13 |
| DrugBank ID |
DB05259
|
| KEGG ID |
D04318
|
| MeSH ID |
D000068717
|
| PubChem ID |
65370
|
| TTD Drug ID |
D04CRL
|
| NDC Product Code |
0378-6961; 41524-0004 |
| UNII |
U782C039QP
|
| Synonyms |
Glatiramer Acetate | Acetate, Glatiramer | Copaxone | Glatiramer | TV 5010 | 5010, TV | TV5010 | TV-5010 |
|
| Chemical Information |
| Molecular Formula |
C23H41N5O11 |
| CAS Registry Number |
28704-27-0 |
| SMILES |
CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
